ProPhase Labs announces preliminary results for dietary supplement Equivir

ProPhase Labs announced positive preliminary results from its Equivir dietary supplement comprehensive trial. Preliminary results indicate that this innovative OTC dietary supplement has the potential to support and maintain immunity, which – if confirmed at the end of the clinical trial program – may help reduce both the frequency and severity of upper respiratory illnesses including the common cold, flu, and Covid-19. Overall, in the initial 150 patient group there were approximately 46 incidences of upper respiratory viral infections. 62.3% of the patients in the placebo group acquired a viral infection versus only 37.7% in the Equivir group. Additional key statistics from the initial findings are: 39% of the placebo population acquired an upper respiratory viral infection vs 22.9% in the Equivir group. After 4 days of illness, only 3% of the Equivir group still had mild symptoms vs 55% in the placebo group. The average severity was 16% less severe when taking Equivir vs the placebo. No patients in the Equivir group became ill a second time while 2 patients in the placebo group had a second upper respiratory viral infection.